The medicines threshold is the benchmark NICE uses to assess whether a new treatment provides sufficient health benefit relative to its cost to justify routine NHS funding.

The Access to Medicines and Medical Devices APPG has written to the Health Minister to raise concerns about ongoing delays in the UK National Screening Committee’s review of newborn screening for Spinal Muscular Atrophy (SMA).

The Access to Medicines and Medical Devices APPG has written to the Health Minister to highlight ongoing challenges with the Early Access Programme (EAP) for Givinostat, a life-changing treatment for Duchenne muscular dystrophy.